FDA Approves Eli Lilly's Obesity Pill, Setting Up Competition with Novo Nordisk

The FDA approved Eli Lilly's oral obesity pill orforglipron, branded as Foundayo, on April 1, 2026, under a controversial commissioner's voucher program linked to White House pricing negotiations. The approval sets up direct competition with Novo Nordisk's Wegovy pill, which gained a four-month head start with December 2025 approval and demonstrated superior 13.6% weight loss versus orforglipron's 11.2% in trials. Both companies priced their pills at up to $299 monthly after Eli Lilly lowered its initially planned $399 price point. Eli Lilly's orforglipron offers a convenience advantage with no food-timing restrictions, while Novo's Wegovy pill requires morning dosing 30 minutes before eating and carries cardiovascular risk reduction approval. The approval has drawn scrutiny over alleged political interference and Eli Lilly pressure on FDA regulators.

FDA approval and market competition between Eli Lilly and Novo Nordisk

• ▪Eli Lilly's obesity pill orforglipron was approved by the Food and Drug Administration on Wednesday, April 1, 2026
• ▪Eli Lilly and Novo Nordisk led the growth of the obesity drug market with the injectable GLP-1 medications Zepbound and Wegovy
• ▪The FDA approved Eli Lilly's Foundayo as tablets with doses ranging up to 17.2 mg, which Eli Lilly said are equivalent to the capsule doses
• ▪Novo Nordisk has seen rapid adoption of the Wegovy pill, which may reduce uptake of Eli Lilly's orforglipron
• ▪Novo Nordisk's Wegovy pill was approved in December 2025, giving Novo Nordisk a head start over Eli Lilly
• ▪Eli Lilly tested Foundayo in Phase 3 trials as capsules with doses ranging up to 36 mg
• ▪Eli Lilly's Foundayo was approved under the FDA's new commissioner's voucher program, which grants speedy reviews to drugs aligned with national health priorities
• ▪Novo Nordisk's Wegovy pill must be taken in the morning at least 30 minutes before any food or drinks other than water

Pricing strategies and patient accessibility

• ▪Novo Nordisk launched the Wegovy pill at a cash price of up to $299 a month, undercutting Eli Lilly's planned pricing
• ▪Eli Lilly announced in 2025 that it planned to sell orforglipron at prices from $149 a month to $399 a month in the cash market
• ▪Eli Lilly lowered its orforglipron price to up to $299 a month for patients who continually renew their prescription

Efficacy and safety profiles of the competing obesity pills

• ▪Novo Nordisk's Wegovy pill is approved to cut the risk of cardiovascular complications
• ▪Eli Lilly's orforglipron showed 11.2% weight loss in its 72-week Phase 3 study
• ▪The most common side effects of Eli Lilly's orforglipron are nausea, vomiting, and diarrhea, similar to other GLP-1 drugs
• ▪Novo Nordisk's Wegovy pill led to 13.6% weight loss in a 64-week Phase 3 trial

Controversy over the FDA's voucher program approval process

• ▪An Eli Lilly spokesperson told Reuters that Eli Lilly expected the FDA to conduct a fulsome review of orforglipron and make a science-based decision
• ▪Eli Lilly received a voucher as part of its deal with the White House to lower the prices of its obesity drugs in certain settings
• ▪Reuters reported that Eli Lilly tried to pressure the FDA to deliver a faster answer on whether the agency considers Eli Lilly's applications complete

Perspective of Novo Nordisk

• ▪Novo Nordisk's Wegovy pill achieved greater weight loss than Eli Lilly's orforglipron in clinical trials, with 13.6% versus 11.2% weight reduction
• ▪Novo Nordisk gained a competitive head start by securing FDA approval for its Wegovy pill four months before Eli Lilly's orforglipron approval

Perspective of FDA agency insiders

• ▪Reuters reported that Eli Lilly tried to pressure the FDA to deliver a faster answer on whether the agency considers Eli Lilly's applications complete